Wedbush Reaffirms “Outperform” Rating for Perspective Therapeutics (NYSE:CATX)

Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report report published on Thursday, Benzinga reports. They currently have a $20.00 price target on the stock.

A number of other research firms also recently issued reports on CATX. Oppenheimer reissued an “outperform” rating and issued a $22.00 price target on shares of Perspective Therapeutics in a research note on Friday, October 11th. Royal Bank of Canada reduced their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Bank of America initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They issued a “buy” rating and a $24.00 price target on the stock. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $20.63.

Perspective Therapeutics Trading Down 3.0 %

NYSE:CATX opened at $11.53 on Thursday. The company has a 50-day moving average price of $13.76. Perspective Therapeutics has a 1-year low of $2.20 and a 1-year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. Equities analysts expect that Perspective Therapeutics will post -0.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bleakley Financial Group LLC acquired a new position in Perspective Therapeutics during the 1st quarter worth approximately $40,000. nVerses Capital LLC acquired a new position in Perspective Therapeutics during the 3rd quarter worth approximately $57,000. Victory Capital Management Inc. acquired a new position in Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd acquired a new position in Perspective Therapeutics during the 2nd quarter worth approximately $118,000. Finally, RIA Advisory Group LLC grew its holdings in Perspective Therapeutics by 1,313.4% during the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after acquiring an additional 99,293 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.